Key result
Hirudin cuts 30-day death or reinfarction vs heparin with streptokinase, but not with t-PA.
Why the study?
In a large-scale trial of patients with acute coronary syndromes, hirudin provided modest benefit compared with heparin, but its differential interaction with thrombolytic agents like streptokinase and tissue-type plasminogen activator had not been specifically assessed.
Does adjunctive hirudin compared with heparin interact differently with streptokinase and t-PA to reduce the incidence of death or reinfarction at 30 days in patients with ST-segment elevation acute myocardial infarction?
RCT (n=3,289)
randomly assigned to receive hirudin or heparin
Does adjunctive hirudin compared with heparin interact differently with streptokinase and t-PA to reduce the incidence of death or reinfarction at 30 days in patients with ST-segment elevation acute myocardial infarction?
Direct thrombin inhibition with hirudin significantly reduces 30-day death or reinfarction compared with heparin when used adjunctively with streptokinase, but offers no advantage when paired with t-PA.
Answers are grounded in this paper and cite their sources.
Hirudin may confer modest benefit over heparin with fibrinolysis in AMI; extends prior ACS data but leaves open relevance in contemporary reperfusion.
Objectives We sought to show that hirudin might interact differently with streptokinase (SK) and tissue-type plasminogen activator (t-PA), which could reduce the incidence of death or reinfarction at 30 days. Background In a large-scale trial of patients with acute coronary syndromes, hirudin provided modest benefit compared with heparin. However, the interaction with thrombolytic agents was not specifically assessed. Methods Patients with symptoms of acute myocardial infarction and electrocardiographic ST segment elevation were treated with thrombolytic therapy and randomly assigned to receive hirudin or heparin. Results A total of 2,274 patients received t-PA, and 1,015 received SK. Baseline characteristics were balanced by antithrombin assignment. Among SK-treated patients, death or reinfarction at 30 days occurred more often in those treated with adjunctive heparin (14.4%) rather than hirudin (8.6%, odds ratio [OR] 1.78, 95% confidence interval [CI] 1.20 to 2.66, p = 0.004). Among t-PA-treated patients, the rates were 10.9% with heparin and 10.3% with hirudin (OR 1.06, 95% CI 0.81 to 1.38, p = 0.68; for treatment heterogeneity: chi-square 4.20, degrees of freedom [df] 1, p = 0.04). After adjustment for baseline differences between thrombolytic groups, the rates were 9.1% for SK with hirudin, 10.3% for t-PA with hirudin, 10.5% for t-PA with heparin and 14.9% for SK with heparin (for treatment heterogeneity: chi-square 4.5, df 1, p = 0.03), suggesting that the beneficial treatment effect of hirudin was limited to the SK-treated patients. Conclusions Hirudin interacts favorably with SK but not t-PA, highlighting the importance of thrombin activity after SK therapy and the potential for simulating the effects of a more potent fibrinolytic agent through direct antithrombin therapy.
No takes yet. Share an insight, caveat, or question.
Metz et al. (1998) conducted an RCT in Acute myocardial infarction with ST-segment elevation (n=3,289). Hirudin vs. Heparin was evaluated on Death or reinfarction at 30 days (OR 1.78, 95% CI 1.20-2.66, p=0.004). Hirudin reduced 30-day death or reinfarction vs heparin with streptokinase, but not with t-PA.
Synapse has enriched 10 related papers. Consider them for comparative context: